Capricor reports Q2 net loss $7.4M; HOPE-3 DMD trial on track for Q4 2023 interim analysis

CAPRICOR THERAPEUTICS, INC.

2023-Q2 EPS reported -$0.60 revenue$6,904,163

Cash, equivalents & marketable securities $37.8M as of June 30, down from $41.4M Dec 31, 2022.
Q2 revenue $3.9M from Nippon Shinyaku upfront recognition vs. $0 in prior year; operating expenses $11.7M vs $7.3M.
HOPE-3 Phase 3 DMD trial: 48 of ~68 patients randomized across 17 sites; enrollment completion and interim analysis expected Q4 2023.
Held FDA Type-B clinical meeting to discuss CAP-1002 BLA pathway; final minutes awaited.
Raised ~$2.1M net via ATM at avg $4.87/share; cash runway through Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CAPRICOR THERAPEUTICS, INC. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the second quarter ended June 30, 2023 and provided a corporate update.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-013590

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.